Fatty liver disease: time to target CCR5?

References

• Younossi ZM, Golabi P, Paik JM, et al. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology. 2023 Apr 1;77(4):1335–1347. doi: 10.1097/HEP.0000000000000004
   PubMed Web of Science ®Google Scholar
• Ratziu V, Tacke F. At the dawn of potent therapeutics for fatty liver disease - introducing the miniseries on promising pharmacological targets for NASH. J Hepatol. 2023 Aug;79(2):261–262. doi: 10.1016/j.jhep.2023.04.003
   PubMed Web of Science ®Google Scholar
• Tacke F, Puengel T, Loomba R, et al. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023 Aug [cited 2023 Apr 14];79(2):552–566. doi: 10.1016/j.jhep.2023.03.038
   PubMed Web of Science ®Google Scholar
• Newsome PN, Ambery P. Incretins (GLP-1 receptor agonists and dual/triple agonists) and the liver. J Hepatol. 2023 Dec [cited 2023 Aug 9];79(6):1557–1565. doi: 10.1016/j.jhep.2023.07.033
   PubMed Web of Science ®Google Scholar
• Hammerich L, Tacke F. Hepatic inflammatory responses in liver fibrosis. Nat Rev Gastroenterol Hepatol. 2023 Oct [cited 2023 Jul 3];20(10):633–646. doi: 10.1038/s41575-023-00807-x
   PubMed Web of Science ®Google Scholar
• Berres ML, Koenen RR, Rueland A, et al. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice. J Clin Invest. 2010 Nov;120(11):4129–4140. doi: 10.1172/JCI41732
   PubMed Web of Science ®Google Scholar
• Shen J, Chen C, Chen Z, et al. CCL5 promotes the proliferation and metastasis of bladder cancer via the JAK2/STAT3 signaling pathway. Transl Androl Urol. 2023 Dec 31;12(12):1845–1858. doi: 10.21037/tau-23-540
   PubMed Web of Science ®Google Scholar
• Tarantino G, Crocetto F, Di Vito C, et al. Association of NAFLD and insulin resistance with non metastatic bladder cancer patients: a cross-sectional retrospective study. J Clin Med. 2021 Jan 18;10(2):346. doi: 10.3390/jcm10020346
   PubMed Web of Science ®Google Scholar
• Gulick RM, Fatkenheuer G, Burnside R, et al. Five-year safety evaluation of maraviroc in HIV-1-infected treatment-experienced patients. J Acquir Immune Defic Syndr. 2014 Jan 1;65(1):78–81. doi: 10.1097/QAI.0b013e3182a7a97a
   PubMed Web of Science ®Google Scholar
• Thompson M, Saag M, DeJesus E, et al. A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus. AIDS. 2016 Mar 27;30(6):869–878. doi: 10.1097/QAD.0000000000000988
   PubMed Web of Science ®Google Scholar
• Sherman KE, Abdel-Hameed E, Rouster SD, et al. Improvement in hepatic fibrosis biomarkers associated with chemokine receptor inactivation through mutation or therapeutic blockade. Clin Infect Dis. 2019 May 17;68(11):1911–1918. doi: 10.1093/cid/ciy807
   PubMed Web of Science ®Google Scholar
• Kurth F, Helbig ET, Lippert LJ, et al. Cenicriviroc for the treatment of COVID-19: first interim results of a randomised, placebo-controlled, investigator-initiated, double-blind phase II trial. J Glob Antimicrob Resist. 2023 Mar [cited 2022 Dec 23];32:44–47. doi: 10.1016/j.jgar.2022.12.004
   PubMed Web of Science ®Google Scholar
• Pérez-Martínez L, Ochoa-Callejero L, Rubio-Mediavilla S, et al. Maraviroc improves hepatic triglyceride content but not inflammation in a murine nonalcoholic fatty liver disease model induced by a chronic exposure to high-fat diet. Transl Res. 2018 Jun;196:17–30. doi: 10.1016/j.trsl.2018.01.004
   PubMed Web of Science ®Google Scholar
• Chan PC, Liao MT, Lu CH, et al. Targeting inhibition of CCR5 on improving obesity-associated insulin resistance and impairment of pancreatic insulin secretion in high fat-fed rodent models. Eur J Pharmacol. 2021 Jan 15;891:173703. doi: 10.1016/j.ejphar.2020.173703
   PubMed Web of Science ®Google Scholar
• Kruger AJ, Fuchs BC, Masia R, et al. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis. Hepatol Commun. 2018 Mar 7;2(5):529–545. doi: 10.1002/hep4.1160
   PubMed Web of Science ®Google Scholar
• Tacke F. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis. Expert Opin Investig Drugs. 2018 Mar;27(3):301–311. doi: 10.1080/13543784.2018.1442436
   PubMed Web of Science ®Google Scholar
• Krenkel O, Puengel T, Govaere O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis. Hepatology. 2018 Apr;67(4):1270–1283. doi: 10.1002/hep.29544
   PubMed Web of Science ®Google Scholar
• Ambade A, Lowe P, Kodys K, et al. Pharmacological inhibition of CCR2/5 signaling prevents and reverses alcohol-induced liver damage, steatosis, and inflammation in mice. Hepatology. 2019 Mar;69(3):1105–1121. doi: 10.1002/hep.30249
   PubMed Web of Science ®Google Scholar
• Ratziu V, Sanyal A, Harrison SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: final analysis of the phase 2b CENTAUR study. Hepatology. 2020 Sep;72(3):892–905. doi: 10.1002/hep.31108
   PubMed Web of Science ®Google Scholar
• Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V, et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA phase III randomized study. Clin Gastroenterol Hepatol. 2024 Jan;22(1):124–134. doi: 10.1016/j.cgh.2023.04.003
   PubMed Web of Science ®Google Scholar
• Ratziu V, Charlton M. Rational combination therapy for NASH: insights from clinical trials and error. J Hepatol. 2023 May;78(5):1073–1079. doi: 10.1016/j.jhep.2022.12.025
   PubMed Web of Science ®Google Scholar
• Puengel T, Lefere S, Hundertmark J, et al. Combined therapy with a CCR2/CCR5 antagonist and FGF21 analogue synergizes in ameliorating steatohepatitis and fibrosis. Int J Mol Sci. 2022 Jun 15;23(12):6696. doi: 10.3390/ijms23126696
   PubMed Web of Science ®Google Scholar
• Anstee QM, Lucas KJ, Francque S, et al. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: results from the phase 2b TANDEM study. Hepatology. 2023 Oct 1;78(4):1223–1239. doi: 10.1097/HEP.0000000000000439
   PubMed Web of Science ®Google Scholar
• Bradshaw D, Abramowicz I, Bremner S, et al. Hepmarc: a 96 week randomised controlled feasibility trial of add-on maraviroc in people with HIV and non-alcoholic fatty liver disease. PLOS ONE. 2023 Jul 14;18(7):e0288598. doi: 10.1371/journal.pone.0288598
   PubMed Web of Science ®Google Scholar
• Seki E, De Minicis S, Gwak GY, et al. CCR1 and CCR5 promote hepatic fibrosis in mice. J Clin Invest. 2009 Jul;119(7):1858–1870. doi: 10.1172/jci37444
   PubMed Web of Science ®Google Scholar
• Bartneck M, Koppe C, Fech V, et al. Roles of CCR2 and CCR5 for hepatic macrophage polarization in mice with liver parenchymal cell-specific NEMO deletion. Cell Mol Gastroenterol Hepatol. 2021 [cited 2020 Sep 4];11(2):327–347. doi: 10.1016/j.jcmgh.2020.08.012
   PubMed Web of Science ®Google Scholar
• Guillot A, Winkler M, Silva Afonso M, et al. Mapping the hepatic immune landscape identifies monocytic macrophages as key drivers of steatohepatitis and cholangiopathy progression. Hepatology. 2023 Jul 1;78(1):150–166. doi: 10.1097/HEP.0000000000000270
   PubMed Web of Science ®Google Scholar